Piedmont Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Piedmont Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,742	Closed	-$1.33M	–	89
2020 Q1	$1.33M	Buy	15,742 +2,277	+17%	+$196K	0.05%	261
2019 Q4	$1.14M	Buy	13,465 +103	+0.8%	+$7.78K	0.04%	309
2019 Q3	$901K	Buy	13,362 +123	+0.9%	+$9.47K	0.03%	346
2019 Q2	$1.13M	Buy	13,239 +349	+3%	+$29.9K	0.05%	299
2019 Q1	$1.15M	Buy	12,890 +60	+0.5%	+$5.56K	0.05%	270
2018 Q4	$1.09M	Buy	12,830 +49	+0.4%	+$4.66K	0.05%	257
2018 Q3	$1.24M	Buy	12,781 +8,932	+232%	+$892K	0.05%	266
2018 Q2	$363K	Sell	3,849 -2,183	-36%	-$191K	0.02%	552
2018 Q1	$489K	Hold	6,032	–	–	0.01%	421
2017 Q4	$538K	Hold	6,032	–	–	0.01%	396
2017 Q3	$561K	Buy	+6,032	New	+$533K	0.01%	391

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Piedmont Investment Advisors's BMRN Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 15,742 shares — an estimated $1.33M sold.

Piedmont Investment Advisors first reported a position in BMRN in Q3 2017 and held it in 11 quarters. The position peaked at $1.33M in Q1 2020. 528 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Piedmont Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Piedmont Investment Advisors sold 15,742 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $1.33M.
Piedmont Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 11 quarters.
Piedmont Investment Advisors's BioMarin Pharmaceuticals position peaked at $1.33M in Q1 2020.
528 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.